Related Experiment Video
Updated: Aug 7, 2026
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes
1Department of Immunology and Cancer Center, Mayo Clinic and Mayo Graduate School, Rochester, Minnesota 55905, USA.
Abstract:
Tumor cells can be effectively recognized and eliminated by CTLs. One approach for the development of CTL-based cancer immunotherapy for solid tumors requires the use of the appropriate immunogenic peptide epitopes that are derived from defined tumor-associated antigens. Because CTL peptide epitopes are restricted to specific MHC alleles, to design immune therapies for the general population it is necessary to identify epitopes for the most commonly found human MHC alleles. The identification of such epitopes has been based on MHC-peptide-binding assays that are costly and labor-intensive. We report here the use of two computer-based prediction algorithms, which are readily available in the public domain (Internet), to identify HL4-B7-restricted CTL epitopes for carcinoembryonic antigen (CEA). These algorithms identified three candidate peptides that we studied for their capacity to induce CTL responses in vitro using lymphocytes from HLA-B7+ normal blood donors. The results show that one of these peptides, CEA9(632) (IPQQHTQVL) was efficient in the induction of primary CTL responses when dendritic cells were used as antigen-presenting cells. These CTLs were efficient in killing tumor cells that express HLA-B7 and produce CEA. The identification of this HLA-B7-restricted CTL epitope will be useful for the design of ethnically unbiased, widely applicable immunotherapies for common solid epithelial tumors expressing CEA. Moreover, our strategy of identifying MHC class I-restricted CTL epitopes without the need of peptide/HLA-binding assays provides a convenient and cost-saving alternative approach to previous methods.
Insights
Researchers identified a specific peptide from carcinoembryonic antigen (CEA) that effectively triggers cytotoxic T lymphocytes (CTLs) in HLA-B7 positive individuals. This discovery offers a promising, cost-effective approach for developing widely applicable cancer immunotherapies against CEA-expressing solid tumors.
Area of Science:
- Immunology
- Oncology
- Computational Biology
Background:
- Cytotoxic T lymphocytes (CTLs) are crucial for eliminating tumor cells.
- Developing effective cancer immunotherapies requires identifying immunogenic peptide epitopes restricted to common human MHC alleles.
- Traditional MHC-peptide binding assays for epitope identification are costly and labor-intensive.
Purpose of the Study:
- To identify HLA-B7-restricted CTL epitopes for carcinoembryonic antigen (CEA) using computational prediction algorithms.
- To evaluate the immunogenicity and tumor-killing capacity of predicted CEA-derived epitopes in vitro.
- To establish a cost-effective and convenient method for discovering MHC class I-restricted CTL epitopes.
Main Methods:
- Utilized two publicly available, computer-based prediction algorithms to identify potential HLA-B7-restricted CTL epitopes from CEA.
- Synthesized three candidate CEA peptides predicted by the algorithms.
- Assessed the ability of these peptides to induce primary CTL responses in vitro using lymphocytes from HLA-B7+ donors and dendritic cells as antigen-presenting cells.
Main Results:
- One identified peptide, CEA9(632) (IPQQHTQVL), efficiently induced primary CTL responses.
- The induced CTLs demonstrated efficacy in killing tumor cells expressing both HLA-B7 and CEA.
- The computational approach successfully identified a functional CTL epitope without relying on traditional binding assays.
Conclusions:
- The identified HLA-B7-restricted CEA epitope (CEA9(632)) is a valuable target for developing broadly applicable immunotherapies against CEA-expressing solid tumors.
- This computational strategy provides a convenient, cost-saving alternative for identifying MHC class I-restricted CTL epitopes, bypassing the need for laborious binding assays.
- The findings contribute to the advancement of personalized and ethnically unbiased cancer immunotherapy.
